Crescendo Bioscience Announces Six Presentations at the American College of Rheumatology 2017 Annual Meeting
October 30 2017 - 7:05AM
Crescendo Bioscience, a wholly-owned subsidiary of Myriad Genetics,
Inc. (NASDAQ:MYGN), today announced that six studies on Vectra® DA
will be featured at the American College of Rheumatology (ACR)
meeting being held Nov. 3-8, 2017 in San Diego, Calif. Vectra
DA has been shown to be the best predictor of the risk of
radiographic progression, and the data from six studies had
demonstrated that a high Vectra DA score was associated with a high
risk of radiographic progression.
"Our presentations at this year’s ACR reinforce our commitment
to improving care for people living with rheumatoid arthritis,"
said Elena Hitraya, M.D., Ph.D., chief medical officer,
Crescendo Bioscience. "The new data add to a robust body of
scientific knowledge supporting Vectra DA, which has been shown in
multiple studies to be the best predictor of the risk of joint
damage in patients with RA."
Please visit Crescendo Biosciences at Booth #712 for information
about Vectra DA. Abstracts are available online at:
https://www.rheumatology.org/Annual-Meeting/Abstracts. Below
is a list of the highlighted Crescendo Bioscience presentations at
ACR (#ACR17):
Podium Presentations
- Title: Effect of age and body mass index (BMI)
on multi-biomarker disease activity (MBDA) score in patients with
rheumatoid arthritis.Presenter: Kerri
Ford.Date: Monday, Nov. 6, 2017: 4:30-6:00 p.m.
PT.Abstract: 1900.
- Title: Validation of biomarkers to predict
flare in polyarticular JIA upon stopping anti-TNF
therapy.Presenter: Daniel
Lovell.Date: Tuesday, Nov. 7, 2017: 4:30-6:00 p.m.
PT.Abstract: 2858.
Poster Presentations
- Title: Impact of the multi-biomarker disease
activity score results on whether rheumatologists changed biologic
therapy for RA patients.Presenter: Jeffrey
Curtis.Date: Sunday, Nov. 5, 2017: 9:00-11:00 a.m.
PT.Abstract: 129.
- Title: High multi-biomarker disease activity
score is associated with high risk of radiographic progression in
six studies.Presenter: Jeffrey
Curtis.Date: Sunday, Nov. 5, 2017: 9:00-11:00 a.m.
PT.Abstract: 438.
- Title: Prediction of cardiovascular events in
rheumatoid arthritis patients using a multi-biomarker of disease
activity.Presenter: Fenglong
Xie.Date: Sunday, Nov. 5, 2017: 9:00-11:00 a.m.
PT.Abstract: 138.
- Title: Development of an adjusted
multi-biomarker disease activity score for rheumatoid arthritis
that accounts for age, sex, and adiposity, with evaluation of
ability to predict risk for radiographic
damage.Presenter: Jeffrey
Curtis.Date: Monday, Nov. 6, 2017: 9:00-11:00 a.m.
PT.Abstract: 1371.
About Rheumatoid ArthritisRheumatoid arthritis
is a chronic, systemic inflammatory condition that is often
characterized by symptoms that include pain, stiffness and
inflammation of the joints, and in some cases, joint destruction
and disability. An estimated 1.5 million Americans have
the condition, which affects nearly three times as many women as
men. While the cause of RA is unknown, many cases are believed to
result from genetic and environmental factors.
About Vectra® DA Vectra DA is the only
multi-biomarker blood test for rheumatoid arthritis disease
activity that integrates the concentrations of 12 serum proteins
associated with RA disease activity into a single objective score,
on a scale of 1 to 100, to help physicians make more informed
treatment decisions. Vectra DA testing is performed at the
Crescendo Bioscience state-of-the-art CLIA (Clinical Laboratory
Improvement Amendments) facility. Test results are reported to the
physician 5 to 7 days from shipping of the specimen to Crescendo
Bioscience. Physicians can receive test results via standard
mail, by fax or via the private web portal, VectraView. For more
information on Vectra DA, please visit: www.Vectra-DA.com.
About Crescendo BioscienceCrescendo Bioscience,
a wholly-owned subsidiary of Myriad Genetics, Inc., is a molecular
diagnostics company dedicated to developing and commercializing
quantitative blood tests for rheumatoid arthritis (RA) and other
autoimmune diseases, located in South San Francisco, Calif.
Crescendo Bioscience develops quantitative, objective, reproducible
blood tests to provide rheumatologists with deeper clinical insight
to help enable more effective management of patients with
autoimmune and inflammatory diseases. For more information,
please visit the company website at www.CrescendoBio.com.
About Myriad GeneticsMyriad Genetics Inc., is a
leading personalized medicine company dedicated to being a trusted
advisor transforming patient lives worldwide with pioneering
molecular diagnostics. Myriad discovers and commercializes
molecular diagnostic tests that: determine the risk of developing
disease, accurately diagnose disease, assess the risk of disease
progression, and guide treatment decisions across six major medical
specialties where molecular diagnostics can significantly improve
patient care and lower healthcare costs. Myriad is focused on
three strategic imperatives: maintaining leadership in an
expanding hereditary cancer market, diversifying its product
portfolio through the introduction of new products and increasing
the revenue contribution from international markets. For more
information on how Myriad is making a difference, please visit the
Company's website: www.myriad.com.
Myriad, the Myriad logo, BART, BRACAnalysis, Colaris, Colaris
AP, EndoPredict, myPath, myRisk, Myriad myRisk, myRisk Hereditary
Cancer, myChoice, myPlan, BRACAnalysis CDx, Tumor BRACAnalysis CDx,
myChoice HRD, Vectra DA, GeneSight, EndoPredict and Prolaris are
trademarks or registered trademarks of Myriad Genetics, Inc. or its
wholly owned subsidiaries in the United States and foreign
countries. MYGN-F, MYGN-G
Safe Harbor StatementThis press release
contains “forward-looking statements” within the meaning of the
Private Securities Litigation Reform Act of 1995, including
statements relating to the Vectra DA data to be presented at the
2017 American College of Rheumatology (ACR) Annual Meeting, Nov.
3-8, 2017 in San Diego, Calif.; our commitment to improving care
for people living with rheumatoid arthritis; the studies which has
shown Vectra DA to be the best predictor of the risk of joint
damage; and the Company’s strategic directives under the caption
“About Myriad Genetics.” These “forward-looking statements” are
based on management’s current expectations of future events and are
subject to a number of risks and uncertainties that could cause
actual results to differ materially and adversely from those
described or implied in the forward-looking statements. These risks
include, but are not limited to: the risk that sales and profit
margins of our existing molecular diagnostic tests and
pharmaceutical and clinical services may decline or will not
continue to increase at historical rates; risks related to our
ability to transition from our existing product portfolio to our
new tests; risks related to changes in the governmental or private
insurers’ reimbursement levels for our tests or our ability to
obtain reimbursement for our new tests at comparable levels to our
existing tests; risks related to increased competition and the
development of new competing tests and services; the risk that we
may be unable to develop or achieve commercial success for
additional molecular diagnostic tests and pharmaceutical and
clinical services in a timely manner, or at all; the risk that we
may not successfully develop new markets for our molecular
diagnostic tests and pharmaceutical and clinical services,
including our ability to successfully generate revenue outside the
United States; the risk that licenses to the technology underlying
our molecular diagnostic tests and pharmaceutical and clinical
services tests and any future tests are terminated or cannot be
maintained on satisfactory terms; risks related to delays or other
problems with operating our laboratory testing facilities; risks
related to public concern over genetic testing in general or our
tests in particular; risks related to regulatory requirements or
enforcement in the United States and foreign countries and changes
in the structure of the healthcare system or healthcare payment
systems; risks related to our ability to obtain new corporate
collaborations or licenses and acquire new technologies or
businesses on satisfactory terms, if at all; risks related to our
ability to successfully integrate and derive benefits from any
technologies or businesses that we license or acquire, including
but not limited to our acquisition of Assurex, Sividon and the
Clinic; risks related to our projections about the potential market
opportunity for our products; the risk that we or our licensors may
be unable to protect or that third parties will infringe the
proprietary technologies underlying our tests; the risk of
patent-infringement claims or challenges to the validity of our
patents; risks related to changes in intellectual property laws
covering our molecular diagnostic tests and pharmaceutical and
clinical services and patents or enforcement in the United States
and foreign countries, such as the Supreme Court decision in the
lawsuit brought against us by the Association for Molecular
Pathology et al; risks of new, changing and competitive
technologies and regulations in the United States and
internationally; the risk that we may be unable to comply with
financial operating covenants under our credit or lending
agreements; the risk that we will be unable to pay, when due,
amounts due under our credit or lending agreements; and other
factors discussed under the heading “Risk Factors” contained in
Item 1A of our most recent Annual Report on Form 10-K, which has
been filed with the Securities and Exchange Commission, as well as
any updates to those risk factors filed from time to time in our
Quarterly Reports on Form 10-Q or Current Reports on Form 8-K.
Media Contact:Ron Rogers(801)
584-3065rrogers@myriad.com
Investor Contact:Scott Gleason(801)
584-1143sgleason@myriad.com
Myriad Genetics (NASDAQ:MYGN)
Historical Stock Chart
From Aug 2024 to Sep 2024
Myriad Genetics (NASDAQ:MYGN)
Historical Stock Chart
From Sep 2023 to Sep 2024